Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3342-3353

  Coukos, George ^a   Makrigiannakis, Antonis ^a   Kang, Eugene H ^a   Rubin, Stephen C ^a   Albelda, Steven M ^a   Molnar Kimber, Katherine L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; PROTEIN P53; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG RESISTANCE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL DEATH; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0033875563     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Sanders, P., Wilkie, N., and Davison, A. Thymidine kinase deletion mutants of herpes simplex virus type 1. J. Gen. Virol., 63: 277-295, 1982.
2. Martuza, R., Malick, A., Markert, J., Ruffner, K., and Coen, D. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (Washington DC), 252: 854-856, 1991.
3. Idowu, A., Fraser-Smith, E., Poffenberger, K., and Herman, R. Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antiviral Res., 17: 145-156, 1992.
4. Kramm, C. M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P. A., Rainov, N. G., Sena-Esteves, M., Aghi, M., Barnett, F. H., Chiocca, E. A., and Breakefield, X. O. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther., 8: 2057-2068, 1997.
5. Boviatsis, E., Scharf, J., Chase, M., Harrington, K., Kowall, N., Breakefield, X., and Chiocca, E. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther., 1: 323-331, 1994.
6. Carroll, N., Chiocca, E., Takahashi, K., and Tanabe, K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg., 224: 323-329, 1996.
7. Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., and Whitley, R. J. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA, 92: 1411-1415, 1995.
8. Kesari, S., Randazzo, B., Valyi-Nagy, T., Huang, Q., Brown, S., MacLean, A., Lee, V., Trojanowski, J., and Fraser, N. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Investig., 73: 636-648, 1995.
9. Mineta, T., Rabkin, S., Yazaki, T., Hunter, W., and Martuza, R. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943, 1995.
10. Bolovan, C. A., Sawtell, N. M., and Thompson, R. L. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol., 68: 48-55, 1994.
11. Brown, S., MacLean, A., Aitken, J., and Harland, J. ICP34.5 influences herpes simplex virus type I maturation and egress from infected cells in vitro. J. Gen. Virol., 75: 3767-3686, 1994.
12. He, B., Gross, M., and Roizman, B. The γ(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the a subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA, 94: 843-848, 1997.
13. MacLean, M., Ul-Fareed, M., Roberson, L., Harland, J., and Brown, S. Herpes simplex virus type 1 deletion variant 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the "a" sequence. J. Gen. Virol., 72: 631-639, 1991.
14. 1 34.5, a gene nonessential for growth in culture. Science (Washington DC), 250: 1262-1265, 1990.
15. Andreansky, S., Soroceanu, L., Flotte, E., Chou, J., Marken, J., Gillespie, G., Roizman, B., and Whitley, R. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res., 57: 1502-1509, 1997.
16. Randazzo, B., Kerasi, S., Gesser, R., Alsop, D., Ford, J., Brown, S., MacLean, A., and Fraser, N. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology, 211: 94-101, 1995.
17. Yazaki, T., Manz, H., Rabkin, S., and Martuza, R. Treatment of human malignant meningiomas by G207, a replication competent multimutated herpes simplex virus 1. Cancer Res., 55: 4752-4756, 1995.
18. Randazzo, B., Bhat, M., Kesari, S., Fraser, N., and Brown, S. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Investig. Dermatol., 108: 933-937, 1997.
19. Toyoizumi, T., Mick, R., Abbas, A. E., Kang, E. H., Kaiser, L. R., and Molnar-Kimber, K. L. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Gene Ther., 10: 3013-3029, 2000.
20. Kucharczuk, J. C., Randazzo, B., Elshami, A. A., Sterman, D. H., Amin, K. A., Molnar-Kimber, K. L., Brown, M. S., Litzky, L. A., Fraser, N. W., Albelda, S. M., and Kaiser, L. R. Use of a replication-restricted, recombinant herpes virus to treat localized human malignancy. Cancer Res., 57: 466-471, 1997.
21. Pyles, R. B., Warnick, R. E., Chalk, C., Szanti, B. E., and Parysek, L. A novel multiply mutated HSV-1 strain for the treatment of human brain tumors. Human Gene Ther., 8: 533-544, 1997.
22. Mineta, T., Rabkin, S., and Martuza, R. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res., 54: 3963-3966, 1994.
23. Toda, M., Rabkin, S. D., and Martuza, R. L. Treatment of human breast cancer in a brain metastatic model by G207, a replication competent multimutated herpes simplex Virus 1. Hum. Gene Ther., 9: 2173-2185, 1998.
24. Kooby, D. A., Carew, J. F., Halterman, M. W., Mack, J. E., Bertino, J. R., Blumgart, L. H., Federoff, H. J., and Fong, Y. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J., 13: 1325-1334, 1999.
25. Carew, J. F., Kooby, D. A., Halterman, M. W., Federoff, H. J., and Fong, Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum. Gene Ther., 10: 1599-1606, 1999.
26. Advani, S. J., Chung, S. M., Yan, S. Y., Gillespie, G. Y., Markert, J. M., Whitley, R. J., Roizman, B., and Weichselbaum, R. R. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res., 59: 2055-2058, 1999.
27. Hunter, W. D., Martuza, R. L., Feigenbaum, F., Todo, T., Mineta, T., Yazaki, T., Toda, M., Newsome, J. T., Platenberg, R. C., Manz, H. J., and Rabkin, S. D. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol., 73: 6319-6326, 1999.
28. Coukos, G., Makrigiannakis, A., Kang, E. H., Capparelli, D., Benjamin, I., Kaiser, L. R., Rubin, S. C., Albelda, S. M., and Molnar-Kimber, K. L. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin. Cancer Res., 5: 1523-1537, 1999.
29. Coukos, G., Rubin, S. C., and Molnar-Kimber, K. L. Application of recombinant herpes simplex virus-1 (HSV-1) for the treatment of malignancies outside the central nervous system. Gene Ther. Mol. Biol., 3: 78-89, 1999.
30. Coukos, G., Makrigiannakis, A., Montas, S., Kaiser, L. R., Albelda, S. M., Rubin, S. M., and Molnar-Kimber, K. L. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther., 7: 275-283, 2000.
31. Ito, M., Watanabe, M., Kamiya, H., and Sakurai, M. Herpes simplex virus type 1 induces apoptosis in peripheral blood T lymphocytes. J. Infect. Dis., 175: 1220-1224, 1997.
32. Galvan, V., and Roizman, B. Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell type-dependent manner. Proc. Natl. Acad. Sci. USA, 95: 3931-3936, 1998.
33. Leopardi, R., van Sant, C., and Roizman, B. The herpes simplex virus 1 protein kinase Us3 is required for protection from apoptosis induced by the virus. Proc. Natl. Acad. Sci. USA, 94: 7891-7896, 1997.
34. Jerome, K. R., Fox, R., Chen, Z., Sears, A. E., Lee, H., and Corey, L. Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J. Virol., 73: 8950-8957, 1999.
35. Aubert, M., O'Toole, J., and Blaho, J. A. Induction and prevention of apoptosis in human HEp-2 cells by herpes simplex virus type 1. J. Virol., 73: 10359-10370, 1999.
36. Gale, M., Jr., and Katze, M. G. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol. Ther., 78: 29-46, 1998.
37. Cuddihy, A. R., Wong, A. H., Tam, N. W., Li, S., and Koromilas, A. E. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene, 18: 2690-2702, 1999.
38. Yeung, M. C., and Lau, A. S. Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells. J. Biol. Chem., 273: 25198-25202, 1998.
39. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
40. el-Deiry, W. S. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol., 9: 79-87, 1997.
41. Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C. A., Gannon, J. V., and Lane, D. P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6: 1699-1703, 1991.
42. Coukos, G., and Rubin, S. Chemotherapy resistance in ovarian cancer; new molecular perspectives. Obstet. Gynecol., 9: 783-792, 1998.
43. Pusztai, L., Siddik, Z. H., Mills, G. B., and Bast, R. C., Jr. Physiologic and pathologic drug resistance in ovarian carcinoma - a hypothesis based on a clonal progression model. Acta Oncol., 37: 629-640, 1998.
44. Johnson, S. W., Ozols, R. F., and Hamilton, T. C. Mechanisms of drug resistance in ovarian cancer. Cancer (Phila.), 71: 644-649, 1993.
45. Parekh, H., Wiesen, K., and Simpkins, H. Acquisition of Taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem. Pharmacol., 53: 461-470, 1997.
46. Yaginuma, Y., and Westphal, H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res., 52: 4196-4199, 1992.
47. Gibb, R. K., Taylor, D. D., Wan, T., O'Connor, D. M., Doering, D. L., and Gercel-Taylor, C. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol. Oncol., 65: 13-22, 1997.
48. Johnson, S. W., Perez, R. P., Godwin, A. K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamilton, T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689-697, 1994.
49. Pestell, K. E., Medlow, C. J., Titley, J. C., Kelland, L. R., and Walton, M. I. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int. J. Cancer, 77: 913-918, 1998.
50. Song, K., Li, Z., Seth, P., Cowan, K. H., and Sinha, B. K. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol. Res., 9: 603-609, 1997.
51. Zeuthen, J., Norgaard, J. O., Avner, P., Fellous, M., Wartiovaara, J., Vaheri, A., Rosen, A., and Giovanella, B. C. Characterization of a human ovarian teratocarcinoma-derived cell line. Int. J. Cancer, 25: 19-32, 1980.
52. Wu, G. S., and El-Deiry, W. S. p53 and chemosensitivity. Nat. Med., 2: 255-256, 1996.
53. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
54. McGahon, A. J., Martin, S. J., Bissonnette, R. P., Mahboubi, A., Shi, Y., Mogil, R. J., Nishioka, W. K., and Green, D. R. The end of the (cell) line: methods for the study of apoptosis in vitro. Methods Cell Biol., 46: 153-185, 1995.
55. Darzynkiewicz, Z., Juan, G., Li, X., Gorczyca, W., Murakami, T., and Traganos, F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry, 27: 1-20, 1997.
56. Molnar-Kimber, K. L., Sterman, D. H., Chang, M., Kang, E. H., Elbash, M., Lanuti, M., Elshami, A., Wilson, J. M., Kaiser, L. R., and Albelda, S. M. Impact of pre-existing humoral and cellular immune responses induced by adenoviral-based gene therapy for localized mesothelioma. Hum. Gene Ther., 9: 2121-2133, 1998.
57. Siddik, Z. H., Mims, B., Lozano, G., and Thai, G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res., 58: 698-703, 1998.
58. Wetzel, C. C., and Berberich, S. J. DNA binding activities of p53 protein following cisplatin damage of ovarian cells. Oncol Res., 10: 151-161, 1998.
59. Zaffaroni, N., Silvestrini, R., Orlandi, L., Bearzatto, A., Gornati, D., and Villa, R. Induction of apoptosis by Taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br. J. Cancer, 77: 1378-1385, 1998.
60. Jones, N. A., Turner, J., McIlwrath, A. J., Brown, R., and Dive, C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol. Pharmacol., 53: 819-826, 1998.
61. McCurrach, M. E., Connor, T. M., Knudson, C. M., Korsmeyer, S. J., and Lowe, S. W. bax deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA, 94: 2345-2349, 1997.
62. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Petty, R., MacLean, A., Harland, J., McKie, E., Mabbs, R., and Brown, S. M. Toxicity evaluation of replication competent herpes simplex virus (ICP34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther., 7: 859-866, 2000.
63. Kastan, M. B., Canman, C. E., and Leonard, C. J. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev., 14: 3-15, 1995.
64. Debernardis, D., Sire, E. G., De Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D'Incalci, M., and Broggini, M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res., 57: 870-874, 1997.
65. Sleijfer, S., Le, T. K., de Jong, S., Timmer-Bosscha, H., Withoff, S., and Mulder, N. H. Combined cytotoxic effects of tumor necrosis factor-α with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53. J. Immunother., 22: 48-53, 1999.
66. Vikhanskaya, F., Clerico, L., Valenti, M., Stanzione, M. S., Broggini, M., Parodi, S., and Russo, P. Mechanism of resistance to cisplatin in a human ovarian carcinoma cell line selected for resistance to doxorubicin: possible role of p53. Int. J. Cancer, 72: 155-159, 1997.
67. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y., Foster, S. A., Demers, G. W., and Galloway, D. A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
68. Elledge, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K., Davidson, N. E., Robert, N., et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. Natl. Cancer Inst., 87: 1254-1256, 1995.
69. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
70. Hamada, M., Fujiwara, T., Hizuta, A., Gochi, A., Naomoto, Y., Takakura, N., Takahashi, K., Roth, J. A., Tanaka, N., and Orita, K. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol., 122: 360-365, 1996.
71. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
72. Gallagher, W. M., and Brown, R. p53-oriented cancer therapies: current progress. Ann. Oncol., 10: 139-150, 1999.
73. Roth, J. A., Swisher, S. G., Merritt, J. A., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., El-Naggar, A. K., Fossella, F. V., Glisson, B. S., Hong, W. K., Khurl, F. R., Kurie, J. M., Nesbitt, J. C., Pisters, K., Putnam, J. B., Schrump, D. S., Shin, D. M., and Walsh, G. L. Gene therapy for non-small cell lung cancer: a preliminary report of a Phase I trial of adenoviral p53 gene replacement. Semin. Oncol., 25: 33-37, 1998.
74. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
75. Kirn, D., Hermiston, T., and McCormick, F. ONYX-015: clinical data are encouraging. Nat. Med., 4: 1341-1342, 1998.
76. Yoon, S. S., Carroll, N. M., Chiocca, E. A., and Tanabe, K. K. Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy. J. Gastrointest. Surg., 3: 34-48, 1999.
77. Chahlavi, A., Todo, T., Martuza, R. L., and Rabkin, S. D. Replication-competent herpes simplex virus vector G207/cisplatin combination therapy for head and neck cancer. Neoplasia, 1: 162-169, 1999.
78. Koyama, A., and Adachi, A. Induction of apoptosis by herpes simplex virus type 1. J. Gen. Virol., 78: 2909-2912, 1997.
79. Ito, M., Koide, W., Watanabe, M., Kamiya, H., and Sakurai, M. Apoptosis of cord blood T lymphocytes by herpes simplex virus type 1. J. Gen. Virol., 78: 1971-1975, 1997.
80. Galvan, V., Brandimarti, R., Munger, J., and Roizman, B. Bcl-2 blocks a caspase-dependent pathway of apoptosis activated by herpes simplex virus 1 infection in Hep-2 cells. J. Virol., 74: 1931-1938, 2000.
81. Galvan, V., Brandimarti, R., and Roizman, B. Herpes simplex virus 1 blocks caspase-3-independent and caspase-dependent pathways to cell death. J. Virol., 73: 3219-3226, 1999.
82. Geiger, K. D., Gurushanthaiah, D., Howes, E. L., Lewandowski, G. A., Reed, J. C., Bloom, F. E., and Sarvetnick, N. E. Cytokine-mediated survival from lethal herpes simplex virus infection: role of programmed neuronal death. Proc. Natl. Acad. Sci. USA., 92: 3411-3415, 1995.
83. L is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol., 70: 398-403, 1998.
84. Brown, S. M., Harland, J., MacLean, A. R., Podlech, J., and Clements, J. B. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J. Gen. Virol., 75: 2367-2377, 1994.